Tesamorelin (1 Vial)

Buy Tesamorelin research-grade peptide from PSPeptides for laboratory studies investigating growth hormone-releasing hormone (GHRH) analog pharmacology, visceral adipose tissue regulation, and metabolic research applications. Tesamorelin is a synthetic 44-amino-acid peptide analog of human GHRH, engineered with an N-terminal trans-3-hexenoic acid modification that provides significantly improved plasma stability compared to native GHRH. Every vial is US-manufactured, third-party HPLC tested at 99%+ purity, and shipped with a batch-specific certificate of analysis for reproducibility in research protocols.

Tesamorelin has one of the most substantial clinical research bases of any research peptide, with multiple large Phase 3 trials, published mechanistic data, and well-characterized pharmacokinetics. It is studied primarily for its selective action on the pituitary-somatotrope axis and its documented effects on visceral adipose tissue reduction. This page provides research-context information about mechanism, published data, comparative pharmacology, and handling considerations. All information is provided for laboratory research use only.

Buy Tesamorelin: Mechanism at the Receptor Level

Tesamorelin binds the growth hormone-releasing hormone receptor (GHRH-R), a class B G-protein-coupled receptor expressed on somatotrope cells in the anterior pituitary. Receptor binding activates adenylyl cyclase via Gs-coupling, elevating intracellular cAMP and triggering pulsatile release of endogenous growth hormone. Because tesamorelin acts upstream at the pituitary rather than replacing GH directly, the resulting GH release preserves the natural pulsatile secretion pattern and downstream feedback regulation via somatostatin.

The critical structural feature that distinguishes tesamorelin from native GHRH is the N-terminal modification: a trans-3-hexenoic acid group replaces the standard tyrosine residue at position 1. This modification confers substantial resistance to enzymatic degradation by dipeptidyl peptidase-IV (DPP-IV), the enzyme responsible for rapidly clearing native GHRH from circulation. Where native GHRH has a plasma half-life of approximately 6-7 minutes, tesamorelin maintains bioactive plasma levels for extended periods, enabling meaningful once-daily research protocols.